Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of olaparib vs physician’s choice chemotherapy in metastatic breast cancer with germline BRCA1/2 mutation
jRCT2080222477Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib in breast cancer (2 arms), sponsored by AstraZeneca. Started Apr 2014; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222477.